
|Videos|November 14, 2017
Dr. Stone on Monitoring Patients With AML
Author(s)Richard M. Stone, MD
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.
Advertisement
Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia (AML).
There are 2 major groups of ways to monitor patients with AML beyond the light microscope, says Stone. The first technique is multiparameter flow cytometry, and the second is based on the mutations in the leukemic cells or specific expression patterns that are present.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Topline LAGOON Results Show Missed OS End Point With Lurbinectedin in Relapsed SCLC
4
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
5






































































